European CHMP recommends license extension of delafloxacin (Quofenix)

The proposed license extension is for the treatment of community- acquired pneumonia in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections.

European Medicines Agency